These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1337 related articles for article (PubMed ID: 24104372)

  • 1. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial.
    Oettle H; Neuhaus P; Hochhaus A; Hartmann JT; Gellert K; Ridwelski K; Niedergethmann M; Zülke C; Fahlke J; Arning MB; Sinn M; Hinke A; Riess H
    JAMA; 2013 Oct; 310(14):1473-81. PubMed ID: 24104372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.
    Oettle H; Post S; Neuhaus P; Gellert K; Langrehr J; Ridwelski K; Schramm H; Fahlke J; Zuelke C; Burkart C; Gutberlet K; Kettner E; Schmalenberg H; Weigang-Koehler K; Bechstein WO; Niedergethmann M; Schmidt-Wolf I; Roll L; Doerken B; Riess H
    JAMA; 2007 Jan; 297(3):267-77. PubMed ID: 17227978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.
    Neoptolemos JP; Palmer DH; Ghaneh P; Psarelli EE; Valle JW; Halloran CM; Faluyi O; O'Reilly DA; Cunningham D; Wadsley J; Darby S; Meyer T; Gillmore R; Anthoney A; Lind P; Glimelius B; Falk S; Izbicki JR; Middleton GW; Cummins S; Ross PJ; Wasan H; McDonald A; Crosby T; Ma YT; Patel K; Sherriff D; Soomal R; Borg D; Sothi S; Hammel P; Hackert T; Jackson R; Büchler MW;
    Lancet; 2017 Mar; 389(10073):1011-1024. PubMed ID: 28129987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial.
    Jones RP; Psarelli EE; Jackson R; Ghaneh P; Halloran CM; Palmer DH; Campbell F; Valle JW; Faluyi O; O'Reilly DA; Cunningham D; Wadsley J; Darby S; Meyer T; Gillmore R; Anthoney A; Lind P; Glimelius B; Falk S; Izbicki JR; Middleton GW; Cummins S; Ross PJ; Wasan H; McDonald A; Crosby T; Ting Y; Patel K; Sherriff D; Soomal R; Borg D; Sothi S; Hammel P; Lerch MM; Mayerle J; Tjaden C; Strobel O; Hackert T; Büchler MW; Neoptolemos JP;
    JAMA Surg; 2019 Nov; 154(11):1038-1048. PubMed ID: 31483448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial.
    Regine WF; Winter KA; Abrams RA; Safran H; Hoffman JP; Konski A; Benson AB; Macdonald JS; Kudrimoti MR; Fromm ML; Haddock MG; Schaefer P; Willett CG; Rich TA
    JAMA; 2008 Mar; 299(9):1019-26. PubMed ID: 18319412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial.
    Neoptolemos JP; Stocken DD; Bassi C; Ghaneh P; Cunningham D; Goldstein D; Padbury R; Moore MJ; Gallinger S; Mariette C; Wente MN; Izbicki JR; Friess H; Lerch MM; Dervenis C; Oláh A; Butturini G; Doi R; Lind PA; Smith D; Valle JW; Palmer DH; Buckels JA; Thompson J; McKay CJ; Rawcliffe CL; Büchler MW;
    JAMA; 2010 Sep; 304(10):1073-81. PubMed ID: 20823433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial.
    Conroy T; Castan F; Lopez A; Turpin A; Ben Abdelghani M; Wei AC; Mitry E; Biagi JJ; Evesque L; Artru P; Lecomte T; Assenat E; Bauguion L; Ychou M; Bouché O; Monard L; Lambert A; Hammel P;
    JAMA Oncol; 2022 Nov; 8(11):1571-1578. PubMed ID: 36048453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial.
    Hammel P; Huguet F; van Laethem JL; Goldstein D; Glimelius B; Artru P; Borbath I; Bouché O; Shannon J; André T; Mineur L; Chibaudel B; Bonnetain F; Louvet C;
    JAMA; 2016 May; 315(17):1844-53. PubMed ID: 27139057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicenter phase II trial to investigate safety and efficacy of gemcitabine combined with cetuximab as adjuvant therapy in pancreatic cancer (ATIP).
    Fensterer H; Schade-Brittinger C; Müller HH; Tebbe S; Fass J; Lindig U; Settmacher U; Schmidt WE; Märten A; Ebert MP; Kornmann M; Hofheinz R; Endlicher E; Brendel C; Barth PJ; Bartsch DK; Michl P; Gress TM;
    Ann Oncol; 2013 Oct; 24(10):2576-2581. PubMed ID: 23897705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of completeness of adjuvant gemcitabine, relapse pattern, and subsequent therapy on outcome of patients with resected pancreatic ductal adenocarcinoma - A pooled analysis of CONKO-001, CONKO-005, and CONKO-006 trials.
    Kurreck A; Weckwerth J; Modest DP; Striefler JK; Bahra M; Bischoff S; Pelzer U; Oettle H; Kruger S; Riess H; Sinn M
    Eur J Cancer; 2021 Jun; 150():250-259. PubMed ID: 33940349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study.
    Van Laethem JL; Hammel P; Mornex F; Azria D; Van Tienhoven G; Vergauwe P; Peeters M; Polus M; Praet M; Mauer M; Collette L; Budach V; Lutz M; Van Cutsem E; Haustermans K
    J Clin Oncol; 2010 Oct; 28(29):4450-6. PubMed ID: 20837948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial.
    Sinn M; Bahra M; Liersch T; Gellert K; Messmann H; Bechstein W; Waldschmidt D; Jacobasch L; Wilhelm M; Rau BM; Grützmann R; Weinmann A; Maschmeyer G; Pelzer U; Stieler JM; Striefler JK; Ghadimi M; Bischoff S; Dörken B; Oettle H; Riess H
    J Clin Oncol; 2017 Oct; 35(29):3330-3337. PubMed ID: 28817370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial.
    Neoptolemos JP; Moore MJ; Cox TF; Valle JW; Palmer DH; McDonald AC; Carter R; Tebbutt NC; Dervenis C; Smith D; Glimelius B; Charnley RM; Lacaine F; Scarfe AG; Middleton MR; Anthoney A; Ghaneh P; Halloran CM; Lerch MM; Oláh A; Rawcliffe CL; Verbeke CS; Campbell F; Büchler MW;
    JAMA; 2012 Jul; 308(2):147-56. PubMed ID: 22782416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meta-analysis on resected pancreatic cancer: a comparison between adjuvant treatments and gemcitabine alone.
    Chen H; He R; Shi X; Zhou M; Zhao C; Zhang H; Qin R
    BMC Cancer; 2018 Oct; 18(1):1034. PubMed ID: 30352573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
    Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
    Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer.
    Ueno H; Kosuge T; Matsuyama Y; Yamamoto J; Nakao A; Egawa S; Doi R; Monden M; Hatori T; Tanaka M; Shimada M; Kanemitsu K
    Br J Cancer; 2009 Sep; 101(6):908-15. PubMed ID: 19690548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical efficacy of adjuvant systemic chemotherapy with gemcitabine in node-positive pancreatic cancer.
    Kurosaki I; Hatakeyama K
    Hepatogastroenterology; 2004; 51(57):634-7. PubMed ID: 15143880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer.
    Deplanque G; Demarchi M; Hebbar M; Flynn P; Melichar B; Atkins J; Nowara E; Moyé L; Piquemal D; Ritter D; Dubreuil P; Mansfield CD; Acin Y; Moussy A; Hermine O; Hammel P
    Ann Oncol; 2015 Jun; 26(6):1194-1200. PubMed ID: 25858497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant systemic chemotherapy with gemcitabine for stage IV pancreatic cancer: a preliminary report of initial experience.
    Kurosaki I; Hatakeyama K
    Chemotherapy; 2005 Oct; 51(6):305-10. PubMed ID: 16224180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human equilibrative nucleoside transporter 1 expression analysed by the clone SP 120 rabbit antibody is not predictive in patients with pancreatic cancer treated with adjuvant gemcitabine - Results from the CONKO-001 trial.
    Sinn M; Riess H; Sinn BV; Stieler JM; Pelzer U; Striefler JK; Oettle H; Bahra M; Denkert C; Bläker H; Lohneis P
    Eur J Cancer; 2015 Aug; 51(12):1546-54. PubMed ID: 26049689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 67.